Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
NCT01088373
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
Azacitidine combined to Lenalidomide
Sponsor
Groupe Francophone des Myelodysplasies
Collaborators
[object Object]